These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20425680)

  • 21. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts.
    Moore MA; Park CB; Tsuda H
    Eur J Cancer Prev; 1998 Apr; 7(2):89-107. PubMed ID: 9818771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes, insulin, and risk of cancer.
    Schiel R; Beltschikow W; Steiner T; Stein G
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):169-75. PubMed ID: 16810343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational use of insulin analogues in the treatment of type 1 diabetes mellitus.
    Bolli GB
    Pediatr Endocrinol Rev; 2003 Sep; 1(1):9-21. PubMed ID: 16437009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes mellitus and the risk of cancer.
    Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
    Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
    Vinik AI; Zhang Q
    Diabetes Care; 2007 Apr; 30(4):795-800. PubMed ID: 17259481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin glargine for type 2 diabetes.
    Hemraj F; Garces K
    Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research.
    Call R; Grimsley M; Cadwallader L; Cialone L; Hill M; Hreish V; King ST; Riche DM
    Postgrad Med; 2010 May; 122(3):158-65. PubMed ID: 20463425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis.
    Nilsen TI; Vatten LJ
    Br J Cancer; 2001 Feb; 84(3):417-22. PubMed ID: 11161410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities.
    Ciaraldi TP; Sasaoka T
    Horm Metab Res; 2011 Jan; 43(1):1-10. PubMed ID: 20938889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitogenic action of insulin: friend, foe or 'frenemy'?
    Draznin B
    Diabetologia; 2010 Feb; 53(2):229-33. PubMed ID: 19851749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Increased risk of cancer using insulin and insulin analogues?].
    Schäffler A
    MMW Fortschr Med; 2010 Sep; 152(36):39-41. PubMed ID: 21192466
    [No Abstract]   [Full Text] [Related]  

  • 37. Type 2 diabetes and cancer: what is the connection?
    Cannata D; Fierz Y; Vijayakumar A; LeRoith D
    Mt Sinai J Med; 2010; 77(2):197-213. PubMed ID: 20309918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of cancer in patients receiving insulin glargine.
    Dawson LK; Hamilton LA
    Am J Health Syst Pharm; 2010 Dec; 67(23):2025-31. PubMed ID: 21098374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes and cancer.
    Chowdhury TA
    QJM; 2010 Dec; 103(12):905-15. PubMed ID: 20739356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
    Gallagher EJ; LeRoith D
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):485-94. PubMed ID: 23974779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.